ArticleBMC cancer2022

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

James C H Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.